ESMO 2017 | Combination therapy to treat ovarian cancer: promising results from the ANANOVA trial

Mansoor Mirza, MD, from the Copenhagen University Hospital, Copenhagen, Denmark discusses the results of the Phase I and II clinical trial ANANOVA (NCT02354131), a study which assessed the efficacy of niraparib alone in comparison to niraparib combined with bevacizumab in treating platinum-sensitive epithelial ovarian cancer. This study follows a previous trial, ANOVA (NCT01847274) which compared niraparib’s efficiency in treating ovarian cancer to standard chemotherapy. Dr Mirza tells us about the encouraging findings of the ANANOVA Phase I trial, and explains the structure and purpose of Phase II. This interview was recorded at the 2017 European Society for Medical Oncology (ESMO) conference held in Madrid, Spain.